Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Covidien

- PMLiVE

Loxo’s cancer drug pair attracts $1.5bn deal with Bayer

The German pharma group will gain full rights to the drugs outside the US

EU flag

Europe’s cancer drug regulation is ‘broken’, claims study

Suggests EMA oncology approvals could lead to wasted funds and patient harm

Merck to co-lead new oncology big data alliance

Will work with Project Data Sphere to improve cancer care

- PMLiVE

BMS and Clovis join forces in PARP combo race

Duo will combine Opdivo and Rubraca in phase II and III trials to treat a variety of tumours

- PMLiVE

BMS and Clovis join forces in PARP combo race

Duo will combine Opdivo and Rubraca in phase II and III trials to treat a variety of tumours

Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships

Anne Legendre reviews the scientific rationale behind immunotherapy combinations and Frances Hendry examines how partnerships, co-marketing and positioning drugs will play key roles in shaping the competitive landscape in oncology.

Blue Latitude Health

- PMLiVE

Keytruda is first FDA-approved drug for molecular indication

Indicates a significant development in the shift towards personalised medicine

National Institute for Health and Care Excellence NICE logo

NICE knocks-back Shire’s pancreatic cancer drug Onivyde

Final guidance rules it's not a cost-effective use of NHS resources

- PMLiVE

Servier cleared to start US trials CAR-T therapy

FDA rules studies of its Pfizer-partnered drug can be resumed

Teva launches online cancer portal My Day

Follows social listening project on gender differences in cancer discussions

EU flag

Italian pharma scandals prompts call for EU-wide pricing probe

Aspen fined €5.2m for threat to halt supply of cancer drugs if price hikes not accepted

Novartis building

Anxiety over CAR-T follows Novartis closure of cell therapy unit

Firm maintains lead ALL project still on course for 2017 filings despite restructuring

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links